董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Bolger | 男 | Director | 70 | 未披露 | 未持股 | 2016-09-29 |
| James J. Mulay | -- | Director | 63 | 未披露 | 未持股 | 2016-09-29 |
| Yun Yen | 男 | Director | 61 | 未披露 | 未持股 | 2016-09-29 |
| Ming Hsieh | 男 | President, Chief Executive Officer and Chairman | 60 | 未披露 | 未持股 | 2016-09-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Kim | 男 | Chief Financial Officer | 49 | 未披露 | 未持股 | 2016-09-29 |
| Hanlin Gao | 男 | Chief Scientific Officer and Lab Director | 50 | 520.45万 | 未持股 | 2016-09-29 |
| Ming Hsieh | 男 | President, Chief Executive Officer and Chairman | 60 | 未披露 | 未持股 | 2016-09-29 |
董事简历
中英对照 | 中文 | 英文- John Bolger
-
John Bolger，他被任命为我们的董事会成员（基于本招股说明书日期）。过去5年里，他已经退休，并担任私人投资者。他也曾担任Tintri Inc（虚拟机存储解决方案的公司）的董事（2016年1月以来）。他拥有广泛的上市公司董事会和审计委员会的经验，也曾担任以下上市公司的多任董事兼审计委员会主席（1993年至2010年），其中包括Integrated Device Technology, Inc.、Sanmina Corp.、Data Race, Inc.、TCSI, Inc.、Integrated Systems, Inc.、Wind River Systems, Inc.、Mission West Property, Inc.、Cogent、Micromuse, Inc.、JNI、Mattson Technology。他也曾担任Cisco Systems, Inc（计算机网络系统的制造商）的副总裁、首席财务官兼首席执行官（1989年至1992年）。他获得the University of Massachusetts的学士学位，以及Harvard University的工商管理硕士学位。他是注册会计师。
John Bolger has served as a member of our board of directors since December 2015. From May 1989 to April 1992 Mr. Bolger served as Vice President of Finance and Administration and Chief Financial Officer of Cisco Systems, Inc. Mr. Bolger has served on the board of directors of Fulgent Genetics, Inc., a technology company focusing on genetic testing, since September 2016. Mr. Bolger previously served on the boards of twelve public companies, including Mattson Technology, Inc., Cogent, Inc., Wind River Systems, Inc., Mission West Properties, Inc. and Integrated Device Technology, Inc. Mr. Bolger holds a bachelor of arts degree from the University of Massachusetts and an MBA from Harvard University. - John Bolger，他被任命为我们的董事会成员（基于本招股说明书日期）。过去5年里，他已经退休，并担任私人投资者。他也曾担任Tintri Inc（虚拟机存储解决方案的公司）的董事（2016年1月以来）。他拥有广泛的上市公司董事会和审计委员会的经验，也曾担任以下上市公司的多任董事兼审计委员会主席（1993年至2010年），其中包括Integrated Device Technology, Inc.、Sanmina Corp.、Data Race, Inc.、TCSI, Inc.、Integrated Systems, Inc.、Wind River Systems, Inc.、Mission West Property, Inc.、Cogent、Micromuse, Inc.、JNI、Mattson Technology。他也曾担任Cisco Systems, Inc（计算机网络系统的制造商）的副总裁、首席财务官兼首席执行官（1989年至1992年）。他获得the University of Massachusetts的学士学位，以及Harvard University的工商管理硕士学位。他是注册会计师。
- John Bolger has served as a member of our board of directors since December 2015. From May 1989 to April 1992 Mr. Bolger served as Vice President of Finance and Administration and Chief Financial Officer of Cisco Systems, Inc. Mr. Bolger has served on the board of directors of Fulgent Genetics, Inc., a technology company focusing on genetic testing, since September 2016. Mr. Bolger previously served on the boards of twelve public companies, including Mattson Technology, Inc., Cogent, Inc., Wind River Systems, Inc., Mission West Properties, Inc. and Integrated Device Technology, Inc. Mr. Bolger holds a bachelor of arts degree from the University of Massachusetts and an MBA from Harvard University.
- James J. Mulay
-
James J. Mulay，被任命为我们的董事会成员（基于本招股说明书日期）。过去5年里，Mulay曾担任the H. Lee Moffitt Comprehensive Cancer Center（位于弗罗里达坦帕）的多种职务，包括Michael McGillicuddy美国参议员Connie Mack & Family黑色素瘤研究和治疗主席、the Immunology and Cutaneous Oncology Programs的高级成员、转化研究中心副主管和细胞疗法主管、美国国家癌症研究所（the National Cancer Institute）和美国食品药品监督管理局（FDA）的特殊政府雇员。Mulay也曾担任Moffitt Technologies Corporation（营利性公司持有各公司股权，拥有the Moffitt Cancer Center的许可知识产权）的董事（2009年以来）。Mulay也任职于多个营利性和非营利性实体的医学、科学、商业和研究顾问委员会。Mulay曾发表了超过180篇的癌症疫苗和癌症免疫疗法领域文章。Mulay于1974年获得New Jersey City University的学士学位，并于1977年获得the University of Washington School of Medicine的细胞免疫学硕士学位。Mulay于1981年获得the University of Washington Graduate School、the Fred Hutchinson Cancer Research Center的肿瘤免疫学博士学位。
James J. Mulay has been appointed as a member of our board of directors as of the date of this prospectus. For the past five years, Dr. Mulé has served in various capacities at the H. Lee Moffitt Comprehensive Cancer Center in Tampa, Florida, including as the Michael McGillicuddy U.S. Senator Connie Mack & Family Endowed Chair in Melanoma Research and Treatment, a Senior Member of both the Immunology and Cutaneous Oncology Programs, Associate Center Director for Translational Research and the Director of Cell-Based Therapies, as well as at the National Cancer Institute and the FDA as a Special Government Employee. Dr. Mulé has also served as a director of Moffitt Technologies Corporation, a for-profit corporation that holds equity in various companies that have licensed intellectual property from the Moffitt Cancer Center, since 2009. Dr. Mulé also sits on numerous medical, scientific, business and research advisory boards of for-profit and non-profit entities and has published over 180 articles in the areas of cancer vaccines and cancer immunotherapy. Dr. Mulé received a B.A. from New Jersey City University in 1974 an M.S. in cellular immunology from the University of Washington School of Medicine in 1977 and an I.Ph.D. in tumor immunology from the University of Washington Graduate School and the Fred Hutchinson Cancer Research Center in 1981. - James J. Mulay，被任命为我们的董事会成员（基于本招股说明书日期）。过去5年里，Mulay曾担任the H. Lee Moffitt Comprehensive Cancer Center（位于弗罗里达坦帕）的多种职务，包括Michael McGillicuddy美国参议员Connie Mack & Family黑色素瘤研究和治疗主席、the Immunology and Cutaneous Oncology Programs的高级成员、转化研究中心副主管和细胞疗法主管、美国国家癌症研究所（the National Cancer Institute）和美国食品药品监督管理局（FDA）的特殊政府雇员。Mulay也曾担任Moffitt Technologies Corporation（营利性公司持有各公司股权，拥有the Moffitt Cancer Center的许可知识产权）的董事（2009年以来）。Mulay也任职于多个营利性和非营利性实体的医学、科学、商业和研究顾问委员会。Mulay曾发表了超过180篇的癌症疫苗和癌症免疫疗法领域文章。Mulay于1974年获得New Jersey City University的学士学位，并于1977年获得the University of Washington School of Medicine的细胞免疫学硕士学位。Mulay于1981年获得the University of Washington Graduate School、the Fred Hutchinson Cancer Research Center的肿瘤免疫学博士学位。
- James J. Mulay has been appointed as a member of our board of directors as of the date of this prospectus. For the past five years, Dr. Mulé has served in various capacities at the H. Lee Moffitt Comprehensive Cancer Center in Tampa, Florida, including as the Michael McGillicuddy U.S. Senator Connie Mack & Family Endowed Chair in Melanoma Research and Treatment, a Senior Member of both the Immunology and Cutaneous Oncology Programs, Associate Center Director for Translational Research and the Director of Cell-Based Therapies, as well as at the National Cancer Institute and the FDA as a Special Government Employee. Dr. Mulé has also served as a director of Moffitt Technologies Corporation, a for-profit corporation that holds equity in various companies that have licensed intellectual property from the Moffitt Cancer Center, since 2009. Dr. Mulé also sits on numerous medical, scientific, business and research advisory boards of for-profit and non-profit entities and has published over 180 articles in the areas of cancer vaccines and cancer immunotherapy. Dr. Mulé received a B.A. from New Jersey City University in 1974 an M.S. in cellular immunology from the University of Washington School of Medicine in 1977 and an I.Ph.D. in tumor immunology from the University of Washington Graduate School and the Fred Hutchinson Cancer Research Center in 1981.
- Yun Yen
-
Yun Yen，他是Lixte Biotechnology Holdings, Inc.的基因检测业务的创始人，并被任命为Lixte Biotechnology Holdings, Inc.的董事会成员。他是Taipei Medical University（位于中国台湾）的总裁兼讲座教授，以及the California Institute of Technology的副教授。他此前曾担任the City of Hope Comprehensive Cancer Center的负责开发癌症治疗的Allen and Lee Chao主席（2008年至2014年）、the City of Hope的分子药理学部门主席、the City of Hope Comprehensive Cancer Center的转化研究副主管（2005年至2014年）。他曾担任许多专业组织的成员，拥有140多项的摘要和同行评审的期刊文章。他于1982年获得Taipei Medical College的医学博士学位，并于1988年获得Thomas Jefferson University的病理和细胞生物学博士学位。
Yun Yen,is President Emeritus of Taipei Medical University (TMU) and Chair Professor of the Ph.D. Program for Cancer Biology and Drug Discovery. Prior to TMU, Dr. Yen was the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics, Chair of Molecular Pharmacology Department, Associate Director for Translational Research, and Co-Director of the Developmental Cancer Therapeutics Program at the City of Hope NCI-designated Comprehensive Cancer Center, Duarte California. He has published more than 300 peer-reviewed articles, holds over 60 patents, and has commercialized multiple methodologies involving nanoparticles, small and large molecule drugs, biomarkers, stem cells, and medical devices. Dr. Yen has also founded philanthropic organizations aimed at serving the global cancer community and holds membership in numerous professional societies. He serves on the boards of Fulgent Genetics and Tanvex BioPharma Inc. - Yun Yen，他是Lixte Biotechnology Holdings, Inc.的基因检测业务的创始人，并被任命为Lixte Biotechnology Holdings, Inc.的董事会成员。他是Taipei Medical University（位于中国台湾）的总裁兼讲座教授，以及the California Institute of Technology的副教授。他此前曾担任the City of Hope Comprehensive Cancer Center的负责开发癌症治疗的Allen and Lee Chao主席（2008年至2014年）、the City of Hope的分子药理学部门主席、the City of Hope Comprehensive Cancer Center的转化研究副主管（2005年至2014年）。他曾担任许多专业组织的成员，拥有140多项的摘要和同行评审的期刊文章。他于1982年获得Taipei Medical College的医学博士学位，并于1988年获得Thomas Jefferson University的病理和细胞生物学博士学位。
- Yun Yen,is President Emeritus of Taipei Medical University (TMU) and Chair Professor of the Ph.D. Program for Cancer Biology and Drug Discovery. Prior to TMU, Dr. Yen was the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics, Chair of Molecular Pharmacology Department, Associate Director for Translational Research, and Co-Director of the Developmental Cancer Therapeutics Program at the City of Hope NCI-designated Comprehensive Cancer Center, Duarte California. He has published more than 300 peer-reviewed articles, holds over 60 patents, and has commercialized multiple methodologies involving nanoparticles, small and large molecule drugs, biomarkers, stem cells, and medical devices. Dr. Yen has also founded philanthropic organizations aimed at serving the global cancer community and holds membership in numerous professional societies. He serves on the boards of Fulgent Genetics and Tanvex BioPharma Inc.
- Ming Hsieh
-
Ming Hsieh自2013年4月起担任董事。Hsieh先生自2012年9月以来，一直担任抗癌药物研究和开发的公司Fulgent Therapeutics Inc.董事长和首席执行官。从2010年10月到2012年6月，Hsieh先生担任全球生物识别解决方案提供商3M Cogent, Inc.总裁，并参与了2010年Cogent, Inc.被3M Company收购。在此次收购之前，Hsieh先生自1990年创立Cogent开始一直担任其首席执行官、总裁和董事长。在此之前，从1985年到1987年，Hsieh先生是半导体制造商International Rectifier Corporation研究及开发工程师。Hsieh先生在1983年取得Southern California大学电机工程学士学位，并在1984年取得电机工程硕士学位。
Ming Hsieh,has served as a member of the Board of Directors since April 2013. Mr. Hsieh has served as the Chairman of the board of directors and Chief Executive Officer of Fulgent Therapeutics Inc., a cancer drug research and development company, since September 2012. From October 2010 to June 2012, Mr. Hsieh served as the President of 3M Cogent, Inc., a provider of global biometric identification solutions, following the acquisition of Cogent, Inc. by 3M Company in 2010. Prior to the acquisition, Mr. Hsieh served as the Chief Executive Officer, President and Chairman of the board of directors of Cogent since founding Cogent in 1990. Prior to that, Mr. Hsieh was a research and development engineer at International Rectifier Corporation, a manufacturer of semiconductors, from 1985 to 1987. Mr. Hsieh received a B.S.E.E. from the University of Southern California in 1983 and an M.S.E.E. from University of Southern California in 1984.Mr. Hsieh has leadership, operational and executive experience by serving as Chief Executive Officer, President and Chairman of the board of directors of Cogent. - Ming Hsieh自2013年4月起担任董事。Hsieh先生自2012年9月以来，一直担任抗癌药物研究和开发的公司Fulgent Therapeutics Inc.董事长和首席执行官。从2010年10月到2012年6月，Hsieh先生担任全球生物识别解决方案提供商3M Cogent, Inc.总裁，并参与了2010年Cogent, Inc.被3M Company收购。在此次收购之前，Hsieh先生自1990年创立Cogent开始一直担任其首席执行官、总裁和董事长。在此之前，从1985年到1987年，Hsieh先生是半导体制造商International Rectifier Corporation研究及开发工程师。Hsieh先生在1983年取得Southern California大学电机工程学士学位，并在1984年取得电机工程硕士学位。
- Ming Hsieh,has served as a member of the Board of Directors since April 2013. Mr. Hsieh has served as the Chairman of the board of directors and Chief Executive Officer of Fulgent Therapeutics Inc., a cancer drug research and development company, since September 2012. From October 2010 to June 2012, Mr. Hsieh served as the President of 3M Cogent, Inc., a provider of global biometric identification solutions, following the acquisition of Cogent, Inc. by 3M Company in 2010. Prior to the acquisition, Mr. Hsieh served as the Chief Executive Officer, President and Chairman of the board of directors of Cogent since founding Cogent in 1990. Prior to that, Mr. Hsieh was a research and development engineer at International Rectifier Corporation, a manufacturer of semiconductors, from 1985 to 1987. Mr. Hsieh received a B.S.E.E. from the University of Southern California in 1983 and an M.S.E.E. from University of Southern California in 1984.Mr. Hsieh has leadership, operational and executive experience by serving as Chief Executive Officer, President and Chairman of the board of directors of Cogent.
高管简历
中英对照 | 中文 | 英文- Paul Kim
Paul Kim，曾担任Fulgent LLC的首席财务官（2016年1月以来），以及我们的首席财务官（2016年5月我们创立以来）。任职我们公司之前，他曾辞职（2011年至2015年），也曾担任Cogent的首席财务官（2004年1月至2011年）。他此前也曾担任JNI Corporation（公开交易的存储区域网络技术公司）的首席财务官（2002年9月至2003年12月）、JNI的财务副总裁兼公司总会计师（1999年10月至2002年8月），以及Datafusion Inc.（一个私人的软件开发公司）的财务行政副总裁（1998年1月至1999年10月）。1996年4月至1998年1月，他曾担任Interlink Computer Sciences, Inc.（上市企业软件公司）的公司总会计师。1990年1月至1996年4月，他曾任职Coopers and Lybrand L.L.P.，并退任审计经理。他于1989年获得the University of California at Berkeley的经济学学士学位，是一个注册会计师。
Paul Kim has served as Fulgent LLC’s Chief Financial Officer since January 2016 and our Chief Financial Officer since our incorporation in May 2016. Prior to his service for us, Mr. Kim was retired from 2011 until 2015 and served as Chief Financial Officer of Cogent from January 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, or JNI, a publicly traded storage area network technology company, from September 2002 until December 2003 as Vice President, Finance and Corporate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from January 1998 until October 1999. From April 1996 to January 1998 Mr. Kim was the Corporate Controller for Interlink Computer Sciences, Inc., a publicly-traded enterprise software company. From January 1990 to April 1996 Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.- Paul Kim，曾担任Fulgent LLC的首席财务官（2016年1月以来），以及我们的首席财务官（2016年5月我们创立以来）。任职我们公司之前，他曾辞职（2011年至2015年），也曾担任Cogent的首席财务官（2004年1月至2011年）。他此前也曾担任JNI Corporation（公开交易的存储区域网络技术公司）的首席财务官（2002年9月至2003年12月）、JNI的财务副总裁兼公司总会计师（1999年10月至2002年8月），以及Datafusion Inc.（一个私人的软件开发公司）的财务行政副总裁（1998年1月至1999年10月）。1996年4月至1998年1月，他曾担任Interlink Computer Sciences, Inc.（上市企业软件公司）的公司总会计师。1990年1月至1996年4月，他曾任职Coopers and Lybrand L.L.P.，并退任审计经理。他于1989年获得the University of California at Berkeley的经济学学士学位，是一个注册会计师。
- Paul Kim has served as Fulgent LLC’s Chief Financial Officer since January 2016 and our Chief Financial Officer since our incorporation in May 2016. Prior to his service for us, Mr. Kim was retired from 2011 until 2015 and served as Chief Financial Officer of Cogent from January 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, or JNI, a publicly traded storage area network technology company, from September 2002 until December 2003 as Vice President, Finance and Corporate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from January 1998 until October 1999. From April 1996 to January 1998 Mr. Kim was the Corporate Controller for Interlink Computer Sciences, Inc., a publicly-traded enterprise software company. From January 1990 to April 1996 Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.
- Hanlin Gao
Hanlin Gao，2012年2月以来，他担任Fulgent LLC的实验室主管。2016年1月他被任命为 Fulgent LLC的首席科学官。2016年9月他被任命为我们实验室主管和首席科学官。他之前的经验包括City of Hope的DNA测序技术核心实验室和临床分子诊断实验室的实验室主管（从2004年到2013年）。2004年加入City of Hope之前，他完成了在Harvard Medical School的临床分子遗传学培训奖学金和博士后奖学金。他获得Peking University的免疫学硕士学位（1993年）和中国Inner Mongolia University for Nationalities医学博士学位（1990年）以及The Ohio State University的微生物学、免疫学和医学遗传学博士学位（2001年）。他是the American Board of Medical Genetics的临床分子遗传学专科医生。他是 the American College of Medical Genetics and Genomics的研究员和CAP的实验室检验团队领导人。
Hanlin Gao has served as Fulgent LLC’s Lab Director since February 2012 was appointed as Fulgent LLC’s Chief Scientific Officer in January 2016 and was appointed as our Lab Director and Chief Scientific Officer in September 2016. Dr. Gao’s prior experience includes service as Lab Director of both the DNA Sequencing Core Laboratory and Clinical Molecular Diagnostics Laboratory at City of Hope from 2004 until 2013. Dr. Gao completed his clinical molecular genetics training fellowship and post-doctoral fellowship at Harvard Medical School in 2004 prior to joining City of Hope. Dr. Gao received a M.S. in Immunology and an M.D. from Peking University and Inner Mongolia University for Nationalities in China in 1993 and 1990 respectively, as well as a Ph.D. in Microbiology, Immunology and Medical Genetics from The Ohio State University in 2001. Dr. Gao is board certified in clinical molecular genetics by the American Board of Medical Genetics, is a Fellow of the American College of Medical Genetics and Genomics and serves as a team leader for laboratory inspections by CAP.- Hanlin Gao，2012年2月以来，他担任Fulgent LLC的实验室主管。2016年1月他被任命为 Fulgent LLC的首席科学官。2016年9月他被任命为我们实验室主管和首席科学官。他之前的经验包括City of Hope的DNA测序技术核心实验室和临床分子诊断实验室的实验室主管（从2004年到2013年）。2004年加入City of Hope之前，他完成了在Harvard Medical School的临床分子遗传学培训奖学金和博士后奖学金。他获得Peking University的免疫学硕士学位（1993年）和中国Inner Mongolia University for Nationalities医学博士学位（1990年）以及The Ohio State University的微生物学、免疫学和医学遗传学博士学位（2001年）。他是the American Board of Medical Genetics的临床分子遗传学专科医生。他是 the American College of Medical Genetics and Genomics的研究员和CAP的实验室检验团队领导人。
- Hanlin Gao has served as Fulgent LLC’s Lab Director since February 2012 was appointed as Fulgent LLC’s Chief Scientific Officer in January 2016 and was appointed as our Lab Director and Chief Scientific Officer in September 2016. Dr. Gao’s prior experience includes service as Lab Director of both the DNA Sequencing Core Laboratory and Clinical Molecular Diagnostics Laboratory at City of Hope from 2004 until 2013. Dr. Gao completed his clinical molecular genetics training fellowship and post-doctoral fellowship at Harvard Medical School in 2004 prior to joining City of Hope. Dr. Gao received a M.S. in Immunology and an M.D. from Peking University and Inner Mongolia University for Nationalities in China in 1993 and 1990 respectively, as well as a Ph.D. in Microbiology, Immunology and Medical Genetics from The Ohio State University in 2001. Dr. Gao is board certified in clinical molecular genetics by the American Board of Medical Genetics, is a Fellow of the American College of Medical Genetics and Genomics and serves as a team leader for laboratory inspections by CAP.
- Ming Hsieh
Ming Hsieh自2013年4月起担任董事。Hsieh先生自2012年9月以来，一直担任抗癌药物研究和开发的公司Fulgent Therapeutics Inc.董事长和首席执行官。从2010年10月到2012年6月，Hsieh先生担任全球生物识别解决方案提供商3M Cogent, Inc.总裁，并参与了2010年Cogent, Inc.被3M Company收购。在此次收购之前，Hsieh先生自1990年创立Cogent开始一直担任其首席执行官、总裁和董事长。在此之前，从1985年到1987年，Hsieh先生是半导体制造商International Rectifier Corporation研究及开发工程师。Hsieh先生在1983年取得Southern California大学电机工程学士学位，并在1984年取得电机工程硕士学位。
Ming Hsieh,has served as a member of the Board of Directors since April 2013. Mr. Hsieh has served as the Chairman of the board of directors and Chief Executive Officer of Fulgent Therapeutics Inc., a cancer drug research and development company, since September 2012. From October 2010 to June 2012, Mr. Hsieh served as the President of 3M Cogent, Inc., a provider of global biometric identification solutions, following the acquisition of Cogent, Inc. by 3M Company in 2010. Prior to the acquisition, Mr. Hsieh served as the Chief Executive Officer, President and Chairman of the board of directors of Cogent since founding Cogent in 1990. Prior to that, Mr. Hsieh was a research and development engineer at International Rectifier Corporation, a manufacturer of semiconductors, from 1985 to 1987. Mr. Hsieh received a B.S.E.E. from the University of Southern California in 1983 and an M.S.E.E. from University of Southern California in 1984.Mr. Hsieh has leadership, operational and executive experience by serving as Chief Executive Officer, President and Chairman of the board of directors of Cogent.- Ming Hsieh自2013年4月起担任董事。Hsieh先生自2012年9月以来，一直担任抗癌药物研究和开发的公司Fulgent Therapeutics Inc.董事长和首席执行官。从2010年10月到2012年6月，Hsieh先生担任全球生物识别解决方案提供商3M Cogent, Inc.总裁，并参与了2010年Cogent, Inc.被3M Company收购。在此次收购之前，Hsieh先生自1990年创立Cogent开始一直担任其首席执行官、总裁和董事长。在此之前，从1985年到1987年，Hsieh先生是半导体制造商International Rectifier Corporation研究及开发工程师。Hsieh先生在1983年取得Southern California大学电机工程学士学位，并在1984年取得电机工程硕士学位。
- Ming Hsieh,has served as a member of the Board of Directors since April 2013. Mr. Hsieh has served as the Chairman of the board of directors and Chief Executive Officer of Fulgent Therapeutics Inc., a cancer drug research and development company, since September 2012. From October 2010 to June 2012, Mr. Hsieh served as the President of 3M Cogent, Inc., a provider of global biometric identification solutions, following the acquisition of Cogent, Inc. by 3M Company in 2010. Prior to the acquisition, Mr. Hsieh served as the Chief Executive Officer, President and Chairman of the board of directors of Cogent since founding Cogent in 1990. Prior to that, Mr. Hsieh was a research and development engineer at International Rectifier Corporation, a manufacturer of semiconductors, from 1985 to 1987. Mr. Hsieh received a B.S.E.E. from the University of Southern California in 1983 and an M.S.E.E. from University of Southern California in 1984.Mr. Hsieh has leadership, operational and executive experience by serving as Chief Executive Officer, President and Chairman of the board of directors of Cogent.